Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-22
2005-02-22
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S058000, C530S300000, C530S402000, C530S407000, C424S070130, C424S094600, C424S278100
Reexamination Certificate
active
06858584
ABSTRACT:
Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
REFERENCES:
patent: 4639433 (1987-01-01), Hunt et al.
patent: 4643987 (1987-02-01), Nagarajan et al.
patent: 4698327 (1987-10-01), Nagarajan et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4983586 (1991-01-01), Bodor
patent: 5024998 (1991-06-01), Bodor
patent: 5134127 (1992-07-01), Stella et al.
patent: 5196404 (1993-03-01), Maraganore et al.
patent: 5324718 (1994-06-01), Loftsson
patent: 5376645 (1994-12-01), Stella et al.
patent: 5472954 (1995-12-01), Loftsson
patent: 5591714 (1997-01-01), Nagarajan et al.
patent: 5602112 (1997-02-01), Rubinfeld
patent: 5624914 (1997-04-01), Patel et al.
patent: 5750509 (1998-05-01), Malabarba et al.
patent: 5776912 (1998-07-01), Patel et al.
patent: 5804568 (1998-09-01), Rubinfeld
patent: 5840684 (1998-11-01), Cooper et al.
patent: 5874418 (1999-02-01), Stella et al.
patent: 5916873 (1999-06-01), Cooper et al.
patent: 5985310 (1999-11-01), Castillo et al.
patent: 6046177 (2000-04-01), Stella et al.
patent: 6048845 (2000-04-01), Rubinfeld
patent: 1222697 (1987-06-01), None
patent: 0149197 (1985-07-01), None
patent: 0335545 (1989-10-01), None
patent: 0463653 (1991-05-01), None
patent: 0667353 (1995-08-01), None
patent: 0816378 (1998-01-01), None
patent: 8200251 (1982-02-01), None
patent: WO 9119734 (1991-12-01), None
patent: WO-9412217 (1994-06-01), None
patent: 9420136 (1994-09-01), None
patent: 9506485 (1995-03-01), None
patent: WO 9511921 (1995-05-01), None
patent: 9855148 (1998-12-01), None
patent: 0039156 (2000-07-01), None
patent: WO-0054751 (2000-09-01), None
patent: 0059528 (2000-10-01), None
patent: WO-0183520 (2001-11-01), None
patent: WO-0198326 (2001-12-01), None
patent: WO-0198327 (2001-12-01), None
patent: WO-0198328 (2001-12-01), None
patent: WO-0198329 (2001-12-01), None
patent: WO-0197851 (2002-03-01), None
Pea, F. et al. (2000) High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improv haemodynamics following cardiac surgical procedures. J. Antimicrob. Chemother. vol. 45, pp. 329-335.*
Uekama, K. et al. (19930 Protective effects of cyclodextrin sulphates against gentamicin-induced nephrotoxicity in the rat. J Pharm Pharmacol. vol. 45, pp. 745-747.*
Giancarlo Agnelli et al., “Effects of Hirudin and Heparin on the Binding of New Fibrin to the Thrombus in t-PA Treated Rabbits”,J. Thrombosis and Haemostasis66, 592-597, 1991.
Paul Bourdon et al., “Structure-function relationships of hirulog peptide interactions with thrombin”,FEBS LETT. 294, 163-166, 1991.
John Dimaio et al., “Bifunctional Thrombin Inhibitors Based on the Sequence of Hirudin45-65*”,J. Biol. Chem265, 21698-21703, 1990.
“Simple Inhibition Systems”,Enzyme Kinetics: Behavior and Analysis of Rapid Equillibrium and Steady-State Enzyme Systems, pp 100-160, John Wiley & Sons, 1975.
J.M. Maraganore et al., “Design and Characterization of Hirologs: A Novel Class of Bivalent Peptide Inhibitors of Thrombin”,Biochemistry29, 7095-7101, 1990.
John F. Morrison et al., “The Behavior and significance of slow-binding enzyme inhibitors”,Adv. in Enzymol, 61, 201-301, 1998.
James C Powers et al., “Synthetic Substrates and Inhibitors of thrombin”,Thrombin: Structure and Function, Chpater 4, (1992) Lawrence J. Berliner, Plenum Press, New York.
Stuart R. Stone et al., “Kinetics of the Inhibition of Thrombin by Hirudin”,Biochemistry25, 4622-4628, 1986.
Zbigniew Szewczuk et al., “Design of a Linker for Trivalent Thrombin Inhibitors: Interaction of the Main Chain of the Linker with Thrombin”,Biochemistry, 32, pp. 3396-3404, 1993 (No. XP-002067819).
Zbigniew Szewczuk et al., “Conformationally Restricted Thrombin Inhibitors Resistant to Proteolytic Digestion”,Biochemistry31, 9132-9140, 1992.
F.B. Taylor et al., “Protein C Prevents the Coagulopathic and Lethal Effects ofEscherichia coliInfusion in the Baboon”J. Clin. Invest., 79, pp. 918-925, 1987.
Yuko Tsuda et al., “Design of Potent Blvalent Thrombin Inhibitors Based on Hirudin Sequence: Incorporation of Nonsubstrate-Type Active Site Inhibitors”,Biochemistry33, pp. 14443-14451, 1994, (No. XP-002067820).
J.I. Witting et al., Hirulog-1 and -B2 thrombin specificity,BioChem J. 287, 663-664, 1992.
Allen, N.E., et al., “The Role of Hydrophobic Side Chains as Determinants of Antibacterial Activity of Semisynthetic Glycopeptide Antibiotics”,The Journal of Antibiotics, 50(8), pp. 677-684, (Aug. 1997).
Ge, M., et al., “Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding”,Science, 284, pp. 507-511, (Apr. 16, 1999).
Nagarajan, R., et al., “Synthesis and Antibacterial Evaluation of N-Alkyl Vancomycins”,The Journal of Antibiotics, XLII(1), pp. 63-72, (Jan. 1989).
Nicolaou, K.C., et al., “Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics”,Angew. Chem. In. Ed., 38, pp. 2097-2152, (1999).
Pavlov, A.Y., et al., “A New Type of Chemical Modification of Glycopeptides Antibiotics: Aminomethylated Derivatives of Eremomycin and Their Antibacterial Activity”,The Journal of Antibiotics, 50(6), pp. 509-513, (Jun. 1997).
Pavlov, A.Y., et al., “Chemical Modification of Glycopeptide Antibiotics [VC1]”,Russian Journal of Bioorganic Chemistry, 24(9), pp. 570-587, (1998).
Pavlov, A.Y., et al., “Mono and Double Modified Teicoplanin Aglycon Derivatives on the Amino Acid No. 7; Structure-activity Relationship”,The Journal of Antibiotics, 51(1), pp. 73-78, (Jan. 1998).
Zhang, M., et al., “A review of recent applications of cyclodextrins for drug discovery”,Expert Opinion on Therapeutic Patents, 9(12), 21 p., (1999).
Conner Michael W.
Judice J. Kevin
Mu YongQi
Pace John L.
Shaw Jeng-Pyng
Hagenah Jeffrey A.
Liu Samuel Wei
Theravance Inc.
LandOfFree
Pharmaceutical compositions containing a glycopeptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions containing a glycopeptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions containing a glycopeptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3489555